Innovative Drugs Sold Under the Special Access Programme Can Receive Data Protection in Canada

May 18, 2011

Tags:

Food and Drug Regulatory Intellectual Property Intellectual Property Litigation Litigation and Dispute Resolution Patents Pharmaceuticals

Related Expertise

Related Insights

Video: Navigating (and challenging) a changing life sciences regulatory environment
COVID-19 triggers Canadian intellectual property deadline extensions until August 31, 2020
Drug pricing and reimbursement: Canada
Indirect comparisons to an innovative drug’s data can trigger data protection provisions
Video: what does a new ruling on Canada’s equivalent to patent term extension mean for the pharmaceutical industry?

Back